The two companies are expanding an existing facility jointly launched in 2018.
They say newly added manufacturing lines will triple the supply capacity of single-use consumables in the Asia-Pacific region.
The adoption of single-use technology is expected to increase rapidly in clinical production and in manufacturing, according to the BioPlan Annual Biomanufacturing report, which noted that more than 85% of current pre-commercial and clinical manufacturing lines/facilities are single-use.
The planned expansion will consist of an additional eight new manufacturing lines, two of which are expected to launch by the end of 2021; with the other six lines scheduled in Q3 2022. It adds 1300 square meters to the manufacturing area of the ISO Class 7 cleanroom and also includes a 1200 square meters warehouse to further save lead time and increase flexibility for customers.
Li Hua, general manager of Cytiva China, told us that “the increased capacity will help the region improve manufacturing resilience with shorter lead times, while maintaining the delivery of high-quality product to our customers within the broader region.”
In addition, Cytiva said it is adding new products, 100L to 1,000L Xcellerex mixer bags, to the expanded facility’s manufacturing portfolio. They will incorporate Fortem technology – the company’s single-use characterized film. “Its local manufacture enhances our ability to provide business continuity for our customers.”
These efforts are part of the US$1.5bn investment announced by Cytiva and Pall Corporation in July this year.